Aurora Cannabis Finalizes Acquisition of CanniMed Therapeutics | CashCropToday
0 Shares 234 Views

Aurora Cannabis Finalizes Acquisition of CanniMed Therapeutics

March 28, 2018
234 Views

Aurora Cannabis (TSX: ACB) (OTCQB: ACBFF) announced this morning that the company has finalized acquisition of 95% of CanniMed Therapeutics (TSX: CMED) outstanding shares to complete “the largest acquisition in cannabis industry history.” Aurora Cannabis plans to acquire the remaining of CanniMeds outstanding shares through compulsory share acquisition.

By completing this transaction, Aurora Cannabis has now added to its portfolio a strongly recognized brand in the medicinal cannabis community. The combined company plans to focus on product and technological development, as well as,  expansion to international markets.

CanniMed has been supplying Health Canada with medicinal cannabis for over a decade and has a collection of over 5,000 physicians referring its cannabis products to patients. Aurora Cannabis believes thats, “CanniMed produces and distributes the most physician-prescribed cannabis oil in the Canadian medical cannabis system.”

The combined company will focus on obtaining EU GMP certification for all of its current and future facilities in an attempt to capture significant market share on the continent of Europe. Aurora Cannabis now has the ability to produce over 280,000 kg of cannabis per year.

Terry Booth, CEO of Aurora Cannabis, stated, ” We believe that our combined assets, capabilities, and brand strength, as well as our consistent execution, position us very well to gain significant share of the global market.”

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
270 views
Market Watch
270 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
194 views
Global
194 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
190 views
Manufacturing
190 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: